Tomahawk, WI 8/01/2013 (Basicsmedia) –Pfizer Inc. (NYSE:PFE), a research and biopharmaceutical firm, develops and manufactures human and animal biologic medicines and nutritional products, managing its portfolio in five segments – Primary care, Specialty care, Emerging market and established products, Consumer and animal healthcare, and Nutrition. Pfizer parted with its nutrition and animal health segments, selling the former to Nestle SA in November 2012 for $11.85 billion, and the latter in February 2013 to Zoetis Inc.

The Company has been looking to revive its business model post divestment of its nutrition and animal health segments. Pfizer announced its plans to split its operations into three units, two for branded and one for its generic products, beginning January, 2014. Also, there is a possibility of Pfizer shedding off its generics arm to concentrate its efforts on branded and patented drugs business in three to four years time. There are expectations within the Company for business in emerging markets to pick up pace during the later half of this year.

Pfizer Inc. reported its 2Q2013 results on Tuesday, July 30, 2013, one day ahead of schedule.

Income for the second quarter was down 10% to $4.00 billion, or $0.56 per share, against the last year figures of $4.45 billion, or $0.59 per share. There was a 7% drop in revenue at $12.97 billion, as against the market analysts’ expectations of $0.55 earnings per share and net revenue at $13.01 billion in the quarter.

Generics business contributes 17% of total sales for the Company but has low margins in terms of profit as compared to patented drugs. Launch of new candidates Inlyta and Xalkori contributed to a 28% increase in revenues from cancer related medicines during the quarter. Pfizer forecast its earnings for fiscal year 2013 between $2.10 and $2.20 per share. Pfizer, Inc. announced a cash dividend of $0.24 per share to be paid on September 4, 2013 to its shareholders of the record as on July 31, 2013. The shares of Pfizer will trade ex-dividend with effect from August 1, 2013.

On July 31, 2013, Pfizer Inc settled with the US Department of Justice by decided to pay $490.9 million in a case of illegal marketing of organ transplant related drug Rapamune. The drug was acquired by Pfizer in 2009, with the acquisition of Wyeth Pharmaceuticals Inc. The drug prevents human body from rejecting a transplanted kidney but was being promoted by Wyeth for use in transplant of other organs by offering cash incentives for its sales. Under the settlement, the Company is required to pay $157.58 million and forfeit assets worth $76 million as criminal fine, and pay $257.4 million under civil settlements to the federal and state governments. Pfizer said that it had “cooperated fully with the government in the case” and that “it was not a target of the Federal Department of Justice.”

Meanwhile, GAVI Alliance and Pfizer, Inc. signed a supply agreement on July 31, 2013 for Pfizer to supply additional consignments of Prevenar 13, a pneumococcal conjugate vaccine used in infants to help protect against the disease in poor countries under an AMC. Pfizer will provide the UNICEF with 260 million additional doses of Prevenar 13, under a reduced price of $3.40 this year and $3.30 per dose through the course of the agreement, expiring 2025.

DISCLAIMER: This content is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.